<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">8896</article-id><article-id pub-id-type="doi">10.25208/vdv8896</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modern approaches to the treatment of chronic urticaria</article-title><trans-title-group xml:lang="ru"><trans-title>Современные подходы к терапии хронической крапивницы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9458-0872</contrib-id><contrib-id contrib-id-type="spin">2287-5062</contrib-id><name-alternatives><name xml:lang="en"><surname>Samtsov</surname><given-names>Alexey V.</given-names></name><name xml:lang="ru"><surname>Самцов</surname><given-names>Алексей Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>avsamtsov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.M. Kirov Military Medical Academy</institution></aff><aff><institution xml:lang="ru">Военно-медицинская академия имени С.М. Киров</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-10-19" publication-format="electronic"><day>19</day><month>10</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-12" publication-format="electronic"><day>12</day><month>12</month><year>2023</year></pub-date><volume>99</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>22</fpage><lpage>28</lpage><history><date date-type="received" iso-8601-date="2023-05-02"><day>02</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-26"><day>26</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Samtsov A.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Самцов А.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Samtsov A.V.</copyright-holder><copyright-holder xml:lang="ru">Самцов А.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/8896">https://vestnikdv.ru/jour/article/view/8896</self-uri><abstract xml:lang="en"><p>The article provides modern definitions and classification of urticaria. The general provisions of the treatment of chronic urticaria, the treatment of which is often very difficult, are outlined. The main provisions of the treatment of urticaria were formulated, according to which the patient should be treated until the rash is completely resolved. In chronic urticaria, it is necessary to identify and eliminate the causes of dermatosis; avoid exposure to identified triggers; increase tolerance; pharmacological treatment should be aimed at preventing the release of mast cell mediators and/or the effects of mast cell mediators. The goal of treatment should be to relieve the symptoms of urticaria as completely as possible, taking into account the safety and quality of life of the patient in each individual case. The importance of identifying and addressing underlying causes and avoiding identified triggers is emphasized. The therapy algorithm is considered in detail, including 4 lines according to the European guidelines and domestic clinical guidelines. Particular attention is paid to the treatment of various subtypes of chronic urticaria. A comparative description of the most effective antihistamines is given.</p></abstract><trans-abstract xml:lang="ru"><p>В статье приводятся современные определения и классификация крапивницы. Излагаются общие положения терапии хронической крапивницы, лечение которой нередко представляет большие сложности. Сформулированы основные положения терапии крапивницы, согласно которым лечить больного следует до полного разрешения высыпаний. При хронической крапивнице необходимо идентифицировать и устранять причины дерматоза, избегать воздействия выявленных триггеров, повышать толерантность, фармакологическое лечение должно быть направлено на предупреждение высвобождения медиаторов тучных клеток и/или эффектов медиаторов тучных клеток. Целью лечения должно быть полное купирование симптомов при крапивнице, насколько это вообще возможно с учетом безопасности и качества жизни пациента в каждом отдельном случае. Подчеркивается важность идентификации и устранения основных причин и избегания выявленных триггеров. Подробно рассматривается алгоритм терапии, включающий четыре линии согласно европейскому руководству и отечественным клиническим рекомендациям. Особое внимание уделяется лечению различных субтипов хронической крапивницы. Приводится сравнительная характеристика наиболее эффективных антигистаминных препаратов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic urticaria</kwd><kwd>diagnostics</kwd><kwd>treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая крапивница</kwd><kwd>диагностика</kwd><kwd>лечение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кубанов А.А., Аравийская Е.А., Галлямова Ю.А., и др. Крапивница: Клинические рекомендации. М., 2020. 54 с. [Kubanov AA, Aravijskaya EA, Gallyamova YuA, et al. Hives: Clinical guidelines. Мoscow; 2020. 54 p. (In Russ.)]</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ring J. Chronic urticaria: new hope for an old disease. J Eur Acad Dermatol Venereol. 2016;30(Suppl5):3–4. doi: 10.1111/jdv.13742</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol. 2010;10(4):362–369. doi: 10.1097/ACI.0b013e32833c79d7</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Grattan CE, Francis DM, Slater NG, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339(8801):1078–1080. doi: 10.1016/0140-6736(92)90666-q</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wagner N, Dirk D, Peveling-Oberhag A, Reese I, Rady-Pizarro U, Mitzel H, et al. A Popular myth — low-histamine diet improves chronic spontaneous urticaria — fact or fiction? J Eur Acad Dermatol Venereol. 2016;31(4):650–655. doi: 10.1111/jdv.13966</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42(6):1030–1032. doi: 10.1016/s0190-9622(00)90299-8</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175–179. doi: 10.1056/NEJMcp011186</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Федеральные клинические рекомендации по диагностике и лечению крапивницы. М.: Российская ассоциация аллергологов и клинических иммунологов, 2015. 34 c. [Federal clinical guidelines for the diagnosis and treatment of urticaria. Moscow: Russian Association of Allergists and Clinical Immunologists; 2015. 34 p. (In Russ.)]</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Grob J-J, Auquier P, Dreyfus I, Ortonne J-P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009;64(4):605–612. doi: 10.1111/j.1398-9995.2008.01913.x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93(2):168–174. doi: 10.2340/00015555-1434</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175–179. doi: 10.1056/NEJMcp011186</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–573.e1. doi: 10.1016/j.jaci.2011.06.010</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209.e5. doi: 10.1016/j.jaci.2011.04.038</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Harrison CA, Bastan R, Peirce MJ, Munday MR, Peachell PT. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol. 2007;150(4):509–518. doi: 10.1038/sj.bjp.0707002</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic "idiopathic" urticaria. Br J Dermatol. 2000;143(2):365–372. doi: 10.1046/j.1365-2133.2000.03664.x</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P. Neo-I-30 Study Group. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55(4):705–709. doi: 10.1016/j.jaad.2006.04.078</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409–413. doi: 10.1111/j.1525-1470.2009.00869.x</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295–297. doi: 10.2340/0001555576295297</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–390.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol. 2018;79(4):617–633. doi: 10.1016/j.jaad.2018.01.023</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Система поддержки принятия врачебных решений аллергология-иммунология. Клинические протоколы лечения. M., 2021. C. 57–80. [Medical decision support system allergology-immunology. Clinical treatment protocols. Moscow; 2021. P. 57–80. (In Russ.)]</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Dermatology Daily 2016, Febr 2.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Maurer M, Church MK, Gonçalo M, Sussman G, Sánchez-Borges M. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(Suppl3):16–32. doi: 10.1111/jdv.13198</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Гущин И.С Цетиризин — эталон Н1 антигистаминного средства. Методические рекомендации. М., 2010. [Gushchin IS. Cetirizine is the H1 standard of an antihistamine: Methodological recommendations. Moscow; 2010. (In Russ.)]</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Карева Е.Н. Выбор антигистаминного препарата: взгляд фармаколога. РМЖ. Медицинское обозрение. 2016;12:811–816. [Kareva EN. The choice of an antihistamine drug: the view of a pharmacologist, breast cancer. RMJ. Medical Review. 2016;12:811–816. (In Russ.)]</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Bocşan CI, Bujor AI, Miron N, Vesa ŞC, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Med J. 2015;32(4):352–358. doi: 10.5152/balkanmedj.2015.15884</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003;52(Suppl1):S49–50. doi: 10.1007/s000110300050</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004;18(4):399–411. doi: 10.1111/j.1472-8206.2004.00254.x</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676–682. doi: 10.1016/j.jaci.2009.11.047</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis. J Allergy Clin Immunol Pract. 2021;9(2):956–970.e57. doi: 10.1016/j.jaip.2020.08.055</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137. doi: 10.1002/14651858.CD006137.pub2</mixed-citation></ref></ref-list></back></article>
